

Liliana F Devizzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2979633/publications.pdf>

Version: 2024-02-01

45
papers

3,718
citations

279701

23
h-index

276775

41
g-index

46
all docs

46
docs citations

46
times ranked

3580
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	0.6	49
2	Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells. , 2021, 9, e002240.		4
3	Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e321-e323.	0.2	0
4	Lenalidomide in Pretreated Patients with Diffuse Large Bâ€Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. <i>Oncologist</i> , 2019, 24, 1246-1252.	1.9	10
5	Radioimmunotherapy in the Transplant Setting. , 2018, , 431-441.		0
6	The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study. <i>Leukemia and Lymphoma</i> , 2017, 58, 226-229.	0.6	6
7	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1905-1912.	0.8	143
8	High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression. <i>Blood Cancer Journal</i> , 2016, 6, e491-e491.	2.8	4
9	Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 783-791.	0.4	35
10	Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. <i>Leukemia and Lymphoma</i> , 2015, 56, 1671-1676.	0.6	22
11	Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the international extranodal lymphoma study group. <i>British Journal of Haematology</i> , 2014, 166, 69-76.	1.2	39
12	Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. <i>Bone Marrow Transplantation</i> , 2014, 49, 485-491.	1.3	10
13	Successful second autologous engraftment after long duration storage of hematopoietic stem cells. <i>Bone Marrow Transplantation</i> , 2013, 48, 1480-1481.	1.3	2
14	Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose ⁹⁰ Y-ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM. <i>Journal of Clinical Oncology</i> , 2013, 31, 2974-2976.	0.8	14
15	The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. <i>American Journal of Hematology</i> , 2013, 88, 1062-1067.	2.0	54
16	Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. <i>Blood</i> , 2012, 120, 3858-3860.	0.6	58
17	Phase II study of sorafenib in patients with relapsed or refractory lymphoma. <i>British Journal of Haematology</i> , 2012, 158, 108-119.	1.2	36
18	CLIP1: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). <i>Annals of Hematology</i> , 2011, 90, 401-408.	0.8	28

#	ARTICLE	IF	CITATIONS
19	Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia. <i>Cancer</i> , 2011, 117, 5074-5084.	2.0	23
20	Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). <i>Annals of Oncology</i> , 2011, 22, 689-695.	0.6	64
21	MALT lymphoma and Kaposi Sarcoma in an HIV-negative patient. <i>American Journal of Hematology</i> , 2010, 85, 815-817.	2.0	2
22	Radioimmunotherapy and secondary leukemia: A case report. <i>Leukemia Research</i> , 2010, 34, e1-e4.	0.4	4
23	Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up. <i>Bone Marrow Transplantation</i> , 2010, 45, 1119-1120.	1.3	9
24	Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. <i>Leukemia and Lymphoma</i> , 2010, 51, 1251-1259.	0.6	34
25	Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1745-1757.	3.3	19
26	High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. <i>Bone Marrow Transplantation</i> , 2009, 43, 509-511.	1.3	25
27	Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. <i>Blood</i> , 2009, 113, 18-27.	0.6	99
28	High-Dose Yttrium-90-ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2008, 26, 5175-5182.	0.8	68
29	Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. <i>Annals of Oncology</i> , 2008, 19, 233-241.	0.6	203
30	Dosimetry in Myeloablative 90Y-Labeled Ibritumomab Tiuxetan Therapy: Possibility of Increasing Administered Activity on the Base of Biological Effective Dose Evaluation. Preliminary Results. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 113-120.	0.7	20
31	Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). <i>Leukemia</i> , 2007, 21, 1802-1811.	3.3	66
32	High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. <i>British Journal of Haematology</i> , 2004, 126, 815-820.	1.2	35
33	Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. <i>Blood</i> , 2004, 103, 2474-2479.	0.6	549
34	Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience. <i>Journal of Clinical Oncology</i> , 2003, 21, 266-272.	0.8	688
35	Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. <i>Blood</i> , 2003, 101, 2489-2495.	0.6	494
36	Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. <i>Blood</i> , 2003, 102, 2741-2745.	0.6	391

#	ARTICLE	IF	CITATIONS
37	Relevance of intraocular involvement in the management of primary central nervous system lymphomas. <i>Annals of Oncology</i> , 2002, 13, 531-538.	0.6	120
38	The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. <i>British Journal of Haematology</i> , 2002, 118, 218-228.	1.2	19
39	Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. <i>Blood</i> , 2000, 96, 864-869.	0.6	201
40	Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. <i>Blood</i> , 2000, 96, 864-869.	0.6	1
41	Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. <i>British Journal of Haematology</i> , 1998, 103, 533-535.	1.2	37
42	Lack of carboplatin activity in malignant lymphomas. <i>European Journal of Cancer</i> , 1996, 32, 2370-2371.	1.3	0
43	Extended-field radiotherapy in favorable stage IA-IIA Hodgkin's disease (Prognostic role of stage). <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 30, 813-819.	0.4	9
44	Early stage Hodgkin's disease: Ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP. <i>European Journal of Cancer</i> , 1993, 29, 24-29.	1.3	22
45	Study of the HLA-DP ²¹ Locus by the Polymerase Chain Reaction Technique in Patients with Hodgkin's Disease. <i>Tumori</i> , 1993, 79, 133-136.	0.6	2